

ATTORNEY DOCKET NO. 37629-0076US

IN THE CLAIMS:

1. (Currently Amended) A filamentous polyphage particle which

(a) contains

(i) a first recombinant vector molecule that comprises a nucleic acid sequence, which encodes a fusion protein of a first member of a multimeric (poly)peptide complex fused to at least part of a filamentous phage coat protein, and that carries or encodes a first selectable and/or screenable property, and

(ii) a second recombinant vector molecule that comprises a nucleic acid sequence, which encodes a second member of a multimeric (poly)peptide complex, and that carries or encodes a second selectable and/or screenable property different from said first property; and

(b) displays said multimeric (poly)peptide complex at its surface.

Claims 2-15 (canceled).

16. (Previously presented) The particle of claim 1, wherein said first vector is a phage vector and said second vector is a phagemid vector.

17. (Previously presented) The particle of claim 1, wherein said first and second vectors are phagemid vectors.

18. (Previously presented) The particle of claim 17, wherein said two phagemid vectors are compatible.

19. (Previously presented) The particle of claim 17, wherein (i) said first phagemid vector comprises a ColE1 origin of replication and said second phagemid vector comprises a p15A plasmid origin of replication; or (ii) said first phagemid vector comprises a p15A origin of replication and said second phagemid vector comprises a ColE1 plasmid origin of replication.

ATTORNEY DOCKET NO. 37629-0076US

20. (Previously presented) The particle of claim 17, wherein (i) said first phagemid vector comprises a ColE1 origin of replication and said second phagemid vector comprises a mutated ColE1 origin of replication; or (ii) said first phagemid vector comprises a mutated ColE1 origin of replication and said second phagemid vector comprises a ColE1 plasmid origin of replication.

21. (Previously presented) The particle of claim 1, wherein said vectors comprise different phage origins of replication.

22. (Previously presented) The particle of claim 1 wherein said vectors are interference resistant.

23. (Previously presented) The particle of claim 1, wherein at least one of said vectors is a phage or phagemid vector having one or more mutations in the phage intergenic region(s) and/or in gene II.

24. (Previously presented) The particle of claim 1, wherein at least one of said vectors is a phage or phagemid vector that is an IR1 mutant or an IR2 mutant.

25. (Currently amended) The particle of claim 1 wherein at least one of said first and said second molecules vectors is a phage or phagemid vector comprising a hybrid nucleic acid sequence of f1-, fd-, and/or M13-mutated sequences.

26. (Currently amended) The particle of claim 16, wherein said phage vector is SEQ ID NO: 31 or a mutant thereof.

27. (Currently amended) The particle of claim 26, wherein said phage vector is a mutant derived from SEQ ID NO: 31 comprising the phage origin of replication from fpep3_1B-IR3seq, the gene II from fpep3_1B-IR3seq, or a combination of said phage origin of replication and said gene II.

ATTORNEY DOCKET NO. 37629-0076US

28-30. (Canceled)

31. (Previously presented) The particle of claim 28, wherein said mutant comprises the combined fd/f1 origin including the mutation G5737>A (2976 in fpep3_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.

32. (Canceled).

33. (Currently amended) The particle of claim 1, wherein any of said vectors that contains the gene VII contains an amber mutation in said gene VII.

34-35. (Canceled)

36. (Previously presented) The particle of claim 1, wherein said phage coat protein is gIIIp or gVIIIp.

37. (Previously presented) The particle of claim 1, wherein said phage particle is infectious by having a full-length copy of gIIIp.

38. (Previously presented) The particle of claim 1, wherein said phage particles are non-infectious by having no full-length copy of gIIIp, said fusion protein being formed with a truncated version of gIIIp, wherein the infectivity can be restored by interaction of the displayed multimeric polypeptide complexes with a corresponding partner coupled to an infectivity-mediating particle.

39. (Previously presented) The particle of claim 38, wherein said truncated gIIIp comprises the C-terminal domain of gIIIp.

40. (Previously presented) The particle of claim 39, wherein said truncated gIIIp is a mutant of phage fCA55.

ATTORNEY DOCKET NO. 37629-0076US

41. (Previously presented) The particle of claim 1, wherein said multimeric polypeptide complex is a functional fragment of an immunoglobulin.

42. (Previously presented) The particle of claim 41, wherein said fragment is an Fv, dsFv or Fab functional fragment.

43. (Currently amended) The particle of claim 1, wherein said first and/or said second selectable and/or screenable property is the ~~transactivation of~~ transcription of (i) a reporter gene selected from the group consisting of beta-galactosidase and alkaline phosphatase; or (ii) a nutritional marker selected from the group consisting of his3 and leu; or (iii) a resistance gene giving resistance to an antibiotic selected from the group consisting of ampicillin, chloramphenicol, kanamycin, zeocin, neomycin, tetracycline and streptomycin.

44. (Previously presented) The particle of claim 23, wherein the mutation is in the phage intergenic region corresponding to position 5986 of f1.

45. (Previously presented) The particle of claim 23, wherein the mutation is in gene II corresponding to position 143 of f1.

46. (Canceled).

47. (New) The particle of claim 27, wherein said mutant comprises combined fd/f1 origin including mutation G5737>A (2976 in fpep3_1B-IR3seq), and/or the mutations G343>A (3989) in gII, and G601>T (4247) in gII/X.

48. (New) The particle of claim 16, wherein said phagemid vector is a mutant derived from SEQ ID NO: 31.

49. (New) The particle of claim 48, wherein said phagemid mutant comprises the phage origin of replication from fpep3_1B-IRseq, the gene II from fpep3_1B-IRseq, or a combination of said phage origin of replication and said gene II.